arrow
E

Eduardo Nobile‐Orazio

irccs humanitas research hospital
H-index:68
Citation Count:1.5万
Views:0

Biography

No content for now.

Education

No content for now.

Work Experience

No content for now.

Honors & Awards

No content for now.

Refining Electrophysiological Criteria in CIDP and MMN: Toward a Unified Definition of Motor Conduction Block and Proximal Temporal Dispersion

在慢性炎性脱髓鞘性多发性神经病和运动神经病中优化电生理标准:迈向运动传导阻滞和近端时间离散的统一定义

2026-09-030
OAAI
Effect of Rituximab on Neurofilament Levels in CIDP: Results From the CIDPRIT Randomized Trial
2026-02-060
PRE
Insight in the Unmet Needs Encountered During the Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy

在慢性炎性脱髓鞘多神经根神经病管理过程中遇到的需求缺口洞察

2025-10-060
OAAI
Large-scale profiling of antibody reactivity to glycolipids in patients with Guillain-Barré syndrome

大范围分析吉兰-巴雷综合征患者对糖脂的抗体反应性

BRAIN
IF11.7
2025-10-012
OAAI
Nerve Conduction Abnormalities Beyond Conduction Block in Multifocal Motor Neuropathy. Impact on Diagnostic Criteria Accuracy

多灶性运动神经病中传导阻滞以外的神经传导异常。对诊断标准准确性的影响

2025-09-230
OAAI
Splicing-based biomarkers define a robust multigene classifier for relapsing-remitting multiple sclerosis

基于剪接的生物标志物定义了复发缓解型多发性硬化症的一个稳健的多基因分类器

2025-08-290
OAAI
Outcome measures in CIDP: A scoping and mapping review

CIDP中的结局指标:一项范围界定与映射综述

2025-08-120
OAAI
Prevalence of hereditary transthyretin amyloidosis in CIDP patients with red flags: a multicenter genetic screening and misdiagnosis analysis

遗传性甲状腺素运载蛋白淀粉样变性在具有红旗标志的CIDP患者中的患病率:一项多中心遗传筛查和误诊分析

2025-07-160
PRE
A Comprehensive Description of the Roadmap to Identify and Validate a Myelin Biomarker

《识别和验证髓鞘生物标志物的路线图全面描述》

2025-07-060
OA
Rituximab versus placebo for chronic inflammatory demyelinating polyradiculoneuropathy: a randomized trial

利妥昔单抗对比安慰剂治疗慢性炎症性脱髓鞘性多发性神经根神经病:一项随机试验

BRAIN
IF11.7
2024-12-102
PRE
Long-Term Follow Up in Anti-Contactin-1 Autoimmune Nodopathy
2024-11-271
OA
Autonomic neuropathy improving after intravenous immunoglobulin therapy
2024-05-110
PRE
Prospective open-label trial with rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy not responding to conventional immune therapies
2024-05-101
PRE
Cytokines and chemokines in patients with chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: A systematic review
2024-04-102
PRE
Chronic inflammatory demyelinating polyneuropathy and HEV antibody status: A case-control study from Lazio, Italy
2024-04-011
OAAI
European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome
2023-10-1024
OAAI
Neuropathic Pain in the Emergency Setting: Diagnosis and Management
2023-09-183
OAAI
What do we mean by long COVID? A scoping review of the cognitive sequelae of SARS-CoV-2 infection
2023-08-2612
OAAI
CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barre Syndrome
2023-06-0618
OA
A Phase 2/3 Placebo-Controlled, Parallel Group, Randomized Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab for Adults with Chronic Inflammatory Demyelinating Polyneuropathy: the ARISE study
2023-04-250
PRE